[
  {
    "ts": "2025-10-30T20:24:25+00:00",
    "headline": "Bristol-Myers Squibb Co (BMY) Q3 2025 Earnings Call Highlights: Strong Growth and Strategic ...",
    "summary": "Bristol-Myers Squibb Co (BMY) reports robust revenue growth and strategic milestones, raising full-year guidance amid competitive challenges.",
    "url": "https://finance.yahoo.com/news/bristol-myers-squibb-co-bmy-202425685.html",
    "source": "GuruFocus.com",
    "provider": "yfinance",
    "raw": {
      "id": "cc2d00be-d1db-3f27-a637-ee93d1bfdae6",
      "content": {
        "id": "cc2d00be-d1db-3f27-a637-ee93d1bfdae6",
        "contentType": "STORY",
        "title": "Bristol-Myers Squibb Co (BMY) Q3 2025 Earnings Call Highlights: Strong Growth and Strategic ...",
        "description": "",
        "summary": "Bristol-Myers Squibb Co (BMY) reports robust revenue growth and strategic milestones, raising full-year guidance amid competitive challenges.",
        "pubDate": "2025-10-30T20:24:25Z",
        "displayTime": "2025-10-30T20:24:25Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/us.finance.gurufocus/e9e3fac232b3138142c044086b38317e",
          "originalWidth": 400,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/CDEwSF91Z9NXQ_1gIDSkng--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/e9e3fac232b3138142c044086b38317e.cf.webp",
              "width": 400,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/V424MG5ugE.SKo4pBilh9A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/e9e3fac232b3138142c044086b38317e.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GuruFocus.com",
          "url": "http://www.gurufocus.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/bristol-myers-squibb-co-bmy-202425685.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bristol-myers-squibb-co-bmy-202425685.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BMY"
            },
            {
              "symbol": "CELG-RT"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-30T20:10:45+00:00",
    "headline": "Dow Jones Stock Merck Tops Expectations, But Gardasil Challenges Remain",
    "summary": "Dow Jones stock Merck topped third-quarter forecasts on Thursday, but shares skidded as its challenges with vaccine Gardasil continued.",
    "url": "https://www.investors.com/news/technology/merck-stock-merck-earnings-q3-2025/?src=A00220&yptr=yahoo",
    "source": "Investor's Business Daily",
    "provider": "yfinance",
    "raw": {
      "id": "f1ce2da3-440a-342b-b74b-5efb2fbd4b11",
      "content": {
        "id": "f1ce2da3-440a-342b-b74b-5efb2fbd4b11",
        "contentType": "STORY",
        "title": "Dow Jones Stock Merck Tops Expectations, But Gardasil Challenges Remain",
        "description": "",
        "summary": "Dow Jones stock Merck topped third-quarter forecasts on Thursday, but shares skidded as its challenges with vaccine Gardasil continued.",
        "pubDate": "2025-10-30T20:10:45Z",
        "displayTime": "2025-10-30T20:10:45Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/f1ce2da3-440a-342b-b74b-5efb2fbd4b11/dow-jones-stock-merck-tops.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/ibd.com/cce97f02a637b980fef0ad1903f625d6",
          "originalWidth": 1000,
          "originalHeight": 563,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/vxqnYXDl6477oEGUC_FqPA--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/cce97f02a637b980fef0ad1903f625d6.cf.webp",
              "width": 1000,
              "height": 563,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/7eIHKagwi7cIFZsRA.yYcA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/cce97f02a637b980fef0ad1903f625d6.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Investor's Business Daily",
          "url": "http://www.investors.com/"
        },
        "canonicalUrl": {
          "url": "https://www.investors.com/news/technology/merck-stock-merck-earnings-q3-2025/?src=A00220&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            },
            {
              "symbol": "CELG-RT"
            },
            {
              "symbol": "BMY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-30T19:36:19+00:00",
    "headline": "Bristol-Myers Squibb (BMY) Stock Trades Up, Here Is Why",
    "summary": "Shares of biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) jumped 4.3% in the morning session after the company posted third-quarter financial results that beat expectations and raised its full-year sales forecast. Total revenues for the quarter came in at $12.22 billion, an increase of 2.8% from the same period a year ago, surpassing analyst estimates. The company also reported adjusted earnings of $1.63 per share, which was better than anticipated. Following these results, Bristol-Mye",
    "url": "https://finance.yahoo.com/news/bristol-myers-squibb-bmy-stock-193619011.html",
    "source": "StockStory",
    "provider": "yfinance",
    "raw": {
      "id": "5b98ed0d-3d18-3bb8-b80d-3a63818724a6",
      "content": {
        "id": "5b98ed0d-3d18-3bb8-b80d-3a63818724a6",
        "contentType": "STORY",
        "title": "Bristol-Myers Squibb (BMY) Stock Trades Up, Here Is Why",
        "description": "",
        "summary": "Shares of biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) jumped 4.3% in the morning session after the company posted third-quarter financial results that beat expectations and raised its full-year sales forecast. Total revenues for the quarter came in at $12.22 billion, an increase of 2.8% from the same period a year ago, surpassing analyst estimates. The company also reported adjusted earnings of $1.63 per share, which was better than anticipated. Following these results, Bristol-Mye",
        "pubDate": "2025-10-30T19:36:19Z",
        "displayTime": "2025-10-30T19:36:19Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/stockstory_922/37b3541337ce2b08e582bdc742879f1c",
          "originalWidth": 1400,
          "originalHeight": 700,
          "caption": "BMY Cover Image",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Gk.7_kJOBQAPS7VxEfLOgw--~B/aD03MDA7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/stockstory_922/37b3541337ce2b08e582bdc742879f1c.cf.webp",
              "width": 1400,
              "height": 700,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/YM1F85oh4xO4w1Qalh6PGw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/stockstory_922/37b3541337ce2b08e582bdc742879f1c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "StockStory",
          "url": "https://stockstory.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/bristol-myers-squibb-bmy-stock-193619011.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bristol-myers-squibb-bmy-stock-193619011.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BMY"
            },
            {
              "symbol": "CELG-RT"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-30T17:16:00+00:00",
    "headline": "Bladder Cancer Market - Global and Regional Analysis and Forecast (2025-2035) Featuring Merck & Co., Bristol Myers Squibb, Astellas Pharma, AstraZeneca, and Johnson & Johnson",
    "summary": "Dublin, Oct. 30, 2025 (GLOBE NEWSWIRE) -- The \"Bladder Cancer Market - A Global and Regional Analysis: Analysis and Forecast, 2025-2035\" has been added to ResearchAndMarkets.com's offering.The market's growth is primarily driven by the rising incidence of bladder cancer, advancements in diagnostic technologies, and the growing availability of innovative treatments such as immunotherapy and targeted therapies for bladder cancer management.Market Lifecycle StageThe market is currently in the expan",
    "url": "https://finance.yahoo.com/news/bladder-cancer-market-global-regional-171600282.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "6af92c38-f84a-3180-bd58-b2c14b050463",
      "content": {
        "id": "6af92c38-f84a-3180-bd58-b2c14b050463",
        "contentType": "STORY",
        "title": "Bladder Cancer Market - Global and Regional Analysis and Forecast (2025-2035) Featuring Merck & Co., Bristol Myers Squibb, Astellas Pharma, AstraZeneca, and Johnson & Johnson",
        "description": "",
        "summary": "Dublin, Oct. 30, 2025 (GLOBE NEWSWIRE) -- The \"Bladder Cancer Market - A Global and Regional Analysis: Analysis and Forecast, 2025-2035\" has been added to ResearchAndMarkets.com's offering.The market's growth is primarily driven by the rising incidence of bladder cancer, advancements in diagnostic technologies, and the growing availability of innovative treatments such as immunotherapy and targeted therapies for bladder cancer management.Market Lifecycle StageThe market is currently in the expan",
        "pubDate": "2025-10-30T17:16:00Z",
        "displayTime": "2025-10-30T17:16:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc",
          "originalWidth": 480,
          "originalHeight": 58,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_MlAqEncKPaKK77zrkRGmQ--~B/aD01ODt3PTQ4MDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc.cf.webp",
              "width": 480,
              "height": 58,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/caWFqk489OEmv3xI33JamQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/bladder-cancer-market-global-regional-171600282.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bladder-cancer-market-global-regional-171600282.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AZN.L"
            },
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "BMY"
            },
            {
              "symbol": "4503.T"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-30T17:13:00+00:00",
    "headline": "Earnings roundup: Alnylam’s down day, Neurocrine’s head scratch and Biogen’s ‘low quality’ win",
    "summary": "Alnylam and Neurocrine shares tumbled despite upbeat sales reports. Elsewhere, Biogen is dealing with what one analyst called “lackluster” appeal and Bristol Myers’ prized schizophrenia drug again underwhelmed.",
    "url": "https://www.biopharmadive.com/news/alnylam-biogen-neurocrine-bristol-biotech-earnings-q3-2025/804289/",
    "source": "BioPharma Dive",
    "provider": "yfinance",
    "raw": {
      "id": "0eafeea5-3ca2-3910-894a-d118f6fbf96a",
      "content": {
        "id": "0eafeea5-3ca2-3910-894a-d118f6fbf96a",
        "contentType": "STORY",
        "title": "Earnings roundup: Alnylam’s down day, Neurocrine’s head scratch and Biogen’s ‘low quality’ win",
        "description": "",
        "summary": "Alnylam and Neurocrine shares tumbled despite upbeat sales reports. Elsewhere, Biogen is dealing with what one analyst called “lackluster” appeal and Bristol Myers’ prized schizophrenia drug again underwhelmed.",
        "pubDate": "2025-10-30T17:13:00Z",
        "displayTime": "2025-10-30T17:13:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/biopharma_dive_768/51a1b38399a119474d83299d411006e6",
          "originalWidth": 1600,
          "originalHeight": 900,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/oOFbKGlSX5QY50.nVRvD9w--~B/aD05MDA7dz0xNjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/biopharma_dive_768/51a1b38399a119474d83299d411006e6.cf.webp",
              "width": 1600,
              "height": 900,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/SINVL4MOEw.1lSbVBqUUCQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/biopharma_dive_768/51a1b38399a119474d83299d411006e6.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "BioPharma Dive",
          "url": "https://biopharmadive.com/"
        },
        "canonicalUrl": {
          "url": "https://www.biopharmadive.com/news/alnylam-biogen-neurocrine-bristol-biotech-earnings-q3-2025/804289/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/earnings-roundup-alnylam-down-day-171300749.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ALNY"
            },
            {
              "symbol": "NBIX"
            },
            {
              "symbol": "BIIB"
            },
            {
              "symbol": "BMY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-30T16:52:00+00:00",
    "headline": "Novo Nordisk Seeks to Outmuscle Pfizer With $9 Billion Bid for Metsera",
    "summary": "Pfizer says ready to ‘pursue all legal avenues to enforce its rights’ against competing bid from Ozempic and Wegovy maker",
    "url": "https://www.wsj.com/health/pharma/novo-nordisk-moves-to-outbid-pfizer-with-up-to-9-billion-offer-for-obesity-drug-developer-metsera-42420b97?siteid=yhoof2&yptr=yahoo",
    "source": "The Wall Street Journal",
    "provider": "yfinance",
    "raw": {
      "id": "9cee98bc-6b8c-3ed8-8200-e5a09c5cd414",
      "content": {
        "id": "9cee98bc-6b8c-3ed8-8200-e5a09c5cd414",
        "contentType": "STORY",
        "title": "Novo Nordisk Seeks to Outmuscle Pfizer With $9 Billion Bid for Metsera",
        "description": "",
        "summary": "Pfizer says ready to ‘pursue all legal avenues to enforce its rights’ against competing bid from Ozempic and Wegovy maker",
        "pubDate": "2025-10-30T16:52:00Z",
        "displayTime": "2025-10-30T16:52:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/9cee98bc-6b8c-3ed8-8200-e5a09c5cd414/novo-nordisk-seeks-to.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/wsj.com/a2c3a542f7caa83e3114583df6bce5b0",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/hRD47STCEvU9ujChU69OPA--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/a2c3a542f7caa83e3114583df6bce5b0.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/w6Dz.dYCC_lnLeUopbDrAQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/wsj.com/a2c3a542f7caa83e3114583df6bce5b0.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Wall Street Journal",
          "url": "http://www.wsj.com/"
        },
        "canonicalUrl": {
          "url": "https://www.wsj.com/health/pharma/novo-nordisk-moves-to-outbid-pfizer-with-up-to-9-billion-offer-for-obesity-drug-developer-metsera-42420b97?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "BMY"
            },
            {
              "symbol": "CELG-RT"
            },
            {
              "symbol": "MTSR"
            },
            {
              "symbol": "NOVO-B.CO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-30T14:40:52+00:00",
    "headline": "Estée Lauder's turnaround plan, Mastercard beats Q3 estimates",
    "summary": "Market Catalysts host Julie Hyman tracks several of the day's top trending stock tickers, including Estée Lauder (EL) beating profit estimates amid its brand turnaround plan, Mastercard (MA) topping third quarter expectations on its top and bottom lines, and Bristol-Myers Squibb (BMY) raising its revenue outlook. To watch more expert insights and analysis on the latest market action, check out more&nbsp;Market Catalysts.",
    "url": "https://finance.yahoo.com/video/est-e-lauders-turnaround-plan-144037550.html",
    "source": "Yahoo Finance Video",
    "provider": "yfinance",
    "raw": {
      "id": "7f8aa9fb-aa62-3eb5-bbb0-57519b708ed5",
      "content": {
        "id": "7f8aa9fb-aa62-3eb5-bbb0-57519b708ed5",
        "contentType": "VIDEO",
        "title": "Estée Lauder's turnaround plan, Mastercard beats Q3 estimates",
        "description": "<p>Market Catalysts host <a data-i13n=\"cpos:1;pos:1\" href=\"https://www.yahoo.com/author/julie-hyman/?.tsrc=fin-srch\">Julie Hyman</a> tracks several of the day's top trending stock tickers, including Estée Lauder (<a data-i13n=\"cpos:2;pos:1\" href=\"https://finance.yahoo.com/quote/EL\">EL</a>) beating profit estimates amid its brand turnaround plan, Mastercard (<a data-i13n=\"cpos:3;pos:1\" href=\"https://finance.yahoo.com/quote/MA\">MA</a>) topping third quarter expectations on its top and bottom lines, and Bristol-Myers Squibb (<a data-i13n=\"cpos:4;pos:1\" href=\"https://finance.yahoo.com/quote/BMY\">BMY</a>) raising its revenue outlook.</p>\n<p>To watch more expert insights and analysis on the latest market action, check out more <a data-i13n=\"cpos:5;pos:1\" href=\"https://finance.yahoo.com/videos/series/market-catalysts/\">Market Catalysts</a>.</p>",
        "summary": "Market Catalysts host Julie Hyman tracks several of the day's top trending stock tickers, including Estée Lauder (EL) beating profit estimates amid its brand turnaround plan, Mastercard (MA) topping third quarter expectations on its top and bottom lines, and Bristol-Myers Squibb (BMY) raising its revenue outlook. To watch more expert insights and analysis on the latest market action, check out more&nbsp;Market Catalysts.",
        "pubDate": "2025-10-30T14:40:52Z",
        "displayTime": "",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://s.yimg.com/os/creatr-uploaded-images/2025-10/61c84360-b59e-11f0-9fdf-2a79231aa79c",
          "originalWidth": 2074,
          "originalHeight": 1168,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Vdc4zy6akaq.f4dVdb7Jcg--~B/aD0xMTY4O3c9MjA3NDthcHBpZD15dGFjaHlvbg--/https://s.yimg.com/os/creatr-uploaded-images/2025-10/61c84360-b59e-11f0-9fdf-2a79231aa79c.cf.webp",
              "width": 2074,
              "height": 1168,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/k3R1f6NvOxLQ2vbJODo.ZA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/os/creatr-uploaded-images/2025-10/61c84360-b59e-11f0-9fdf-2a79231aa79c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Yahoo Finance Video",
          "url": "https://finance.yahoo.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/video/est-e-lauders-turnaround-plan-144037550.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/video/est-e-lauders-turnaround-plan-144037550.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MA"
            },
            {
              "symbol": "EL"
            },
            {
              "symbol": "BMY"
            },
            {
              "symbol": "CELG-RT"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-30T14:32:00+00:00",
    "headline": "BMY Beats on Q3 Earnings and Sales, Raises 2025 Sales View",
    "summary": "Bristol-Myers' strong Q3 results, powered by Opdivo, Reblozyl and Breyanzi, led to a revenue guidance boost despite legacy drug declines.",
    "url": "https://finance.yahoo.com/news/bmy-beats-q3-earnings-sales-143200442.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "a1a68dd9-85c6-378d-a917-df14410e1065",
      "content": {
        "id": "a1a68dd9-85c6-378d-a917-df14410e1065",
        "contentType": "STORY",
        "title": "BMY Beats on Q3 Earnings and Sales, Raises 2025 Sales View",
        "description": "",
        "summary": "Bristol-Myers' strong Q3 results, powered by Opdivo, Reblozyl and Breyanzi, led to a revenue guidance boost despite legacy drug declines.",
        "pubDate": "2025-10-30T14:32:00Z",
        "displayTime": "2025-10-30T14:32:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/52b6d392b63705aefb517365eab38a95",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/AZ1NFKr1Arip4UWINeWStw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/52b6d392b63705aefb517365eab38a95.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/zL5_evNVQm1N5N.bc6WldQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/52b6d392b63705aefb517365eab38a95.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/bmy-beats-q3-earnings-sales-143200442.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bmy-beats-q3-earnings-sales-143200442.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "CELG-RT"
            },
            {
              "symbol": "BMY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-30T13:30:04+00:00",
    "headline": "Bristol Myers (BMY) Reports Q3 Earnings: What Key Metrics Have to Say",
    "summary": "The headline numbers for Bristol Myers (BMY) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.",
    "url": "https://finance.yahoo.com/news/bristol-myers-bmy-reports-q3-133004768.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "be1a91f9-87be-3251-b22b-4ece26bce5d6",
      "content": {
        "id": "be1a91f9-87be-3251-b22b-4ece26bce5d6",
        "contentType": "STORY",
        "title": "Bristol Myers (BMY) Reports Q3 Earnings: What Key Metrics Have to Say",
        "description": "",
        "summary": "The headline numbers for Bristol Myers (BMY) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.",
        "pubDate": "2025-10-30T13:30:04Z",
        "displayTime": "2025-10-30T13:30:04Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/0c6f98f4bf655bec3b199bc1a71b8b85",
          "originalWidth": 900,
          "originalHeight": 636,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/eN0EvS2DQjGO_6Aa8hYV4w--~B/aD02MzY7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/0c6f98f4bf655bec3b199bc1a71b8b85.cf.webp",
              "width": 900,
              "height": 636,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/IXPNK2bXbxtvuH6_.DBDbA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/0c6f98f4bf655bec3b199bc1a71b8b85.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/bristol-myers-bmy-reports-q3-133004768.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bristol-myers-bmy-reports-q3-133004768.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BMY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-30T13:21:34+00:00",
    "headline": "Bristol-Myers Squibb (NYSE:BMY) Reports Bullish Q3",
    "summary": "Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) reported revenue ahead of Wall Streets expectations in Q3 CY2025, with sales up 2.8% year on year to $12.22 billion. The company’s full-year revenue guidance of $47.75 billion at the midpoint came in 0.9% above analysts’ estimates. Its non-GAAP profit of $1.63 per share was 7.6% above analysts’ consensus estimates.",
    "url": "https://finance.yahoo.com/news/bristol-myers-squibb-nyse-bmy-132134380.html",
    "source": "StockStory",
    "provider": "yfinance",
    "raw": {
      "id": "60293881-778f-35f5-84d8-df1367a4a116",
      "content": {
        "id": "60293881-778f-35f5-84d8-df1367a4a116",
        "contentType": "STORY",
        "title": "Bristol-Myers Squibb (NYSE:BMY) Reports Bullish Q3",
        "description": "",
        "summary": "Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) reported revenue ahead of Wall Streets expectations in Q3 CY2025, with sales up 2.8% year on year to $12.22 billion. The company’s full-year revenue guidance of $47.75 billion at the midpoint came in 0.9% above analysts’ estimates. Its non-GAAP profit of $1.63 per share was 7.6% above analysts’ consensus estimates.",
        "pubDate": "2025-10-30T13:21:34Z",
        "displayTime": "2025-10-30T13:21:34Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/stockstory_922/37b3541337ce2b08e582bdc742879f1c",
          "originalWidth": 1400,
          "originalHeight": 700,
          "caption": "BMY Cover Image",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Gk.7_kJOBQAPS7VxEfLOgw--~B/aD03MDA7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/stockstory_922/37b3541337ce2b08e582bdc742879f1c.cf.webp",
              "width": 1400,
              "height": 700,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/YM1F85oh4xO4w1Qalh6PGw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/stockstory_922/37b3541337ce2b08e582bdc742879f1c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "StockStory",
          "url": "https://stockstory.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/bristol-myers-squibb-nyse-bmy-132134380.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bristol-myers-squibb-nyse-bmy-132134380.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BMY"
            },
            {
              "symbol": "CELG-RT"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-30T12:58:00+00:00",
    "headline": "United States Vitiligo Market Research Report 2025-2033 by Diseases Type, Treatment Type, End User, Regions and Company Analysis",
    "summary": "The United States vitiligo market is projected to grow from $202.87 million in 2024 to $320.71 million by 2033, driven by a 5.22% CAGR from 2025. This growth is fueled by increasing awareness, innovative therapies, and improved diagnostic methods. Key treatment advancements include biologics, phototherapy, and topical solutions. Challenges include limited curative options and high treatment costs. States like California, New York, Texas, and Florida lead due to strong healthcare infrastructure.",
    "url": "https://finance.yahoo.com/news/united-states-vitiligo-market-research-125800265.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "4000caea-533c-3211-a48f-64c2ed1aafad",
      "content": {
        "id": "4000caea-533c-3211-a48f-64c2ed1aafad",
        "contentType": "STORY",
        "title": "United States Vitiligo Market Research Report 2025-2033 by Diseases Type, Treatment Type, End User, Regions and Company Analysis",
        "description": "",
        "summary": "The United States vitiligo market is projected to grow from $202.87 million in 2024 to $320.71 million by 2033, driven by a 5.22% CAGR from 2025. This growth is fueled by increasing awareness, innovative therapies, and improved diagnostic methods. Key treatment advancements include biologics, phototherapy, and topical solutions. Challenges include limited curative options and high treatment costs. States like California, New York, Texas, and Florida lead due to strong healthcare infrastructure.",
        "pubDate": "2025-10-30T12:58:00Z",
        "displayTime": "2025-10-30T12:58:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/7d6d2bc4cce3ea1a3d8cef2378a86dc7",
          "originalWidth": 600,
          "originalHeight": 400,
          "caption": "U.S. Vitiligo Market",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/v8YxAJLeLlUnMSaITHeHyw--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/7d6d2bc4cce3ea1a3d8cef2378a86dc7.cf.webp",
              "width": 600,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/sJL.u69I7e2PbnYhIrBX4g--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/7d6d2bc4cce3ea1a3d8cef2378a86dc7.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/united-states-vitiligo-market-research-125800265.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/united-states-vitiligo-market-research-125800265.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "INCY"
            },
            {
              "symbol": "BMY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-30T12:27:58+00:00",
    "headline": "Are Wall Street Analysts Predicting Bristol-Myers Squibb Stock Will Climb or Sink?",
    "summary": "Bristol-Myers Squibb has significantly underperformed the broader market over the past year, and analysts are cautious about the stock’s prospects.",
    "url": "https://www.barchart.com/story/news/35792126/are-wall-street-analysts-predicting-bristol-myers-squibb-stock-will-climb-or-sink",
    "source": "Barchart",
    "provider": "yfinance",
    "raw": {
      "id": "e7a939b4-6a34-306a-bc60-6b10933236f5",
      "content": {
        "id": "e7a939b4-6a34-306a-bc60-6b10933236f5",
        "contentType": "STORY",
        "title": "Are Wall Street Analysts Predicting Bristol-Myers Squibb Stock Will Climb or Sink?",
        "description": "",
        "summary": "Bristol-Myers Squibb has significantly underperformed the broader market over the past year, and analysts are cautious about the stock’s prospects.",
        "pubDate": "2025-10-30T12:27:58Z",
        "displayTime": "2025-10-30T12:27:58Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/barchart_com_477/274574e1087b6c22ee87eee0dcb266a8",
          "originalWidth": 887,
          "originalHeight": 1183,
          "caption": "Bristol-Myers Squibb Co_ logo on building-by tatu Campelo via iStock",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/X66tq9zV8vSDHQnc_5N4fw--~B/aD0xMTgzO3c9ODg3O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/barchart_com_477/274574e1087b6c22ee87eee0dcb266a8.cf.webp",
              "width": 887,
              "height": 1183,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/iHZBJXJb5FaJ7jG3vePFMA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/barchart_com_477/274574e1087b6c22ee87eee0dcb266a8.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barchart",
          "url": "https://www.barchart.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barchart.com/story/news/35792126/are-wall-street-analysts-predicting-bristol-myers-squibb-stock-will-climb-or-sink",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/wall-street-analysts-predicting-bristol-122758050.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BMY"
            },
            {
              "symbol": "^SPX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-30T12:10:02+00:00",
    "headline": "Bristol Myers Squibb (BMY) Q3 Earnings and Revenues Surpass Estimates",
    "summary": "Bristol Myers (BMY) delivered earnings and revenue surprises of +10.14% and +3.33%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?",
    "url": "https://finance.yahoo.com/news/bristol-myers-squibb-bmy-q3-121002652.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "259c4883-5388-3269-9dc1-de53f0d3d34f",
      "content": {
        "id": "259c4883-5388-3269-9dc1-de53f0d3d34f",
        "contentType": "STORY",
        "title": "Bristol Myers Squibb (BMY) Q3 Earnings and Revenues Surpass Estimates",
        "description": "",
        "summary": "Bristol Myers (BMY) delivered earnings and revenue surprises of +10.14% and +3.33%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?",
        "pubDate": "2025-10-30T12:10:02Z",
        "displayTime": "2025-10-30T12:10:02Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/d2f7ed3d1940141716bfd200f5c94c6b",
          "originalWidth": 900,
          "originalHeight": 711,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Bjs59nqcRE8iEsudL3mMxA--~B/aD03MTE7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/d2f7ed3d1940141716bfd200f5c94c6b.cf.webp",
              "width": 900,
              "height": 711,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Bro_swiyYm6CQ_YbyBgC9g--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/d2f7ed3d1940141716bfd200f5c94c6b.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/bristol-myers-squibb-bmy-q3-121002652.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bristol-myers-squibb-bmy-q3-121002652.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BMY"
            },
            {
              "symbol": "CELG-RT"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-30T11:38:20+00:00",
    "headline": "Bristol-Myers Squibb ups annual outlook as Q3 print exceeds estimates",
    "summary": "Investing.com -- Bristol-Myers Squibb lifted its full-year outlook slightly after reporting third-quarter earnings and revenue that beat market expectations.",
    "url": "https://finance.yahoo.com/news/bristol-myers-squibb-ups-annual-113820823.html",
    "source": "Investing.com",
    "provider": "yfinance",
    "raw": {
      "id": "005556b2-7a62-3873-9fbc-e9f8b3d97073",
      "content": {
        "id": "005556b2-7a62-3873-9fbc-e9f8b3d97073",
        "contentType": "STORY",
        "title": "Bristol-Myers Squibb ups annual outlook as Q3 print exceeds estimates",
        "description": "",
        "summary": "Investing.com -- Bristol-Myers Squibb lifted its full-year outlook slightly after reporting third-quarter earnings and revenue that beat market expectations.",
        "pubDate": "2025-10-30T11:38:20Z",
        "displayTime": "2025-10-30T11:38:20Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "Investing.com",
          "url": "https://www.investing.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/bristol-myers-squibb-ups-annual-113820823.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bristol-myers-squibb-ups-annual-113820823.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BMY"
            },
            {
              "symbol": "CELG-RT"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-30T11:32:00+00:00",
    "headline": "Bristol Myers Squibb Stock Rises After Solid Earnings. But These Problems Remain.",
    "summary": "Bristol Myers Squibb  hiked its full-year guidance on the back of a strong third quarter underlined by demand for drugs within its growth portfolio.  The pharmaceutical giant raised its full-year revenue guidance to a range of $47.5 billion to $48 billion from a previous forecast of $46.5 billion to $47.5 billion.  Bristol Myers now sees adjusted earnings between $6.40 and $6.60 a share, versus a previous range of $6.35 to $6.65 a share.",
    "url": "https://www.barrons.com/articles/bristol-myers-squibb-earnings-stock-price-a0bddbf7?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "470079f2-c372-3f1e-9f0a-d6d3c0ef0a52",
      "content": {
        "id": "470079f2-c372-3f1e-9f0a-d6d3c0ef0a52",
        "contentType": "STORY",
        "title": "Bristol Myers Squibb Stock Rises After Solid Earnings. But These Problems Remain.",
        "description": "",
        "summary": "Bristol Myers Squibb  hiked its full-year guidance on the back of a strong third quarter underlined by demand for drugs within its growth portfolio.  The pharmaceutical giant raised its full-year revenue guidance to a range of $47.5 billion to $48 billion from a previous forecast of $46.5 billion to $47.5 billion.  Bristol Myers now sees adjusted earnings between $6.40 and $6.60 a share, versus a previous range of $6.35 to $6.65 a share.",
        "pubDate": "2025-10-30T11:32:00Z",
        "displayTime": "2025-10-30T11:32:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/470079f2-c372-3f1e-9f0a-d6d3c0ef0a52/bristol-myers-squibb-stock.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/3a06592a1b336b88ec7e35554c4f347e",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/VBcbVe7HNtnHGllxzMdwZA--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/3a06592a1b336b88ec7e35554c4f347e.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/nNBIA82f2roI34jciRypSQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/3a06592a1b336b88ec7e35554c4f347e.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/bristol-myers-squibb-earnings-stock-price-a0bddbf7?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BMY"
            },
            {
              "symbol": "CELG-RT"
            },
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-30T11:11:00+00:00",
    "headline": "Bristol Myers Squibb Profit Soars, Raises Revenue Guidance",
    "summary": "Bristol Myers Squibb added nearly $1 billion to its bottom line in the third quarter as costs came down and revenue climbed on the strength of its newer drugs.",
    "url": "https://www.wsj.com/business/earnings/bristol-myers-squibb-profit-soars-raises-revenue-guidance-536f405c?siteid=yhoof2&yptr=yahoo",
    "source": "The Wall Street Journal",
    "provider": "yfinance",
    "raw": {
      "id": "f0a4bf93-d0dc-3728-8fbf-d7268a423c5e",
      "content": {
        "id": "f0a4bf93-d0dc-3728-8fbf-d7268a423c5e",
        "contentType": "STORY",
        "title": "Bristol Myers Squibb Profit Soars, Raises Revenue Guidance",
        "description": "",
        "summary": "Bristol Myers Squibb added nearly $1 billion to its bottom line in the third quarter as costs came down and revenue climbed on the strength of its newer drugs.",
        "pubDate": "2025-10-30T11:11:00Z",
        "displayTime": "2025-10-30T11:11:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/f0a4bf93-d0dc-3728-8fbf-d7268a423c5e/bristol-myers-squibb-profit.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/wsj.com/dfce97869fd9f06dc6224dedc3e3e15d",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/SduMj9Em29pB7LHuCkmkjw--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/dfce97869fd9f06dc6224dedc3e3e15d.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/0xWh_ksuGBdR._umQaXrTw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/wsj.com/dfce97869fd9f06dc6224dedc3e3e15d.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Wall Street Journal",
          "url": "http://www.wsj.com/"
        },
        "canonicalUrl": {
          "url": "https://www.wsj.com/business/earnings/bristol-myers-squibb-profit-soars-raises-revenue-guidance-536f405c?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BMY"
            },
            {
              "symbol": "CELG-RT"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-30T11:10:02+00:00",
    "headline": "Bristol Myers: Q3 Earnings Snapshot",
    "summary": "PRINCETON, N.J. (AP) — Bristol Myers Squibb Co. (BMY) on Thursday reported third-quarter earnings of $2.2 billion. On a per-share basis, the Princeton, New Jersey-based company said it had profit of $1.08. Earnings, adjusted for non-recurring costs, came to $1.63 per share.",
    "url": "https://finance.yahoo.com/news/bristol-myers-q3-earnings-snapshot-111002765.html",
    "source": "Associated Press Finance",
    "provider": "yfinance",
    "raw": {
      "id": "f7c8d194-d864-3cb7-8950-8b89dd95620b",
      "content": {
        "id": "f7c8d194-d864-3cb7-8950-8b89dd95620b",
        "contentType": "STORY",
        "title": "Bristol Myers: Q3 Earnings Snapshot",
        "description": "",
        "summary": "PRINCETON, N.J. (AP) — Bristol Myers Squibb Co. (BMY) on Thursday reported third-quarter earnings of $2.2 billion. On a per-share basis, the Princeton, New Jersey-based company said it had profit of $1.08. Earnings, adjusted for non-recurring costs, came to $1.63 per share.",
        "pubDate": "2025-10-30T11:10:02Z",
        "displayTime": "2025-10-30T11:10:02Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "Associated Press Finance",
          "url": "http://www.ap.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/bristol-myers-q3-earnings-snapshot-111002765.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bristol-myers-q3-earnings-snapshot-111002765.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BMY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-30T10:59:00+00:00",
    "headline": "Bristol Myers Squibb Reports Third Quarter Financial Results for 2025",
    "summary": "PRINCETON, N.J., October 30, 2025--Bristol Myers Squibb Reports Third Quarter Financial Results for 2025",
    "url": "https://finance.yahoo.com/news/bristol-myers-squibb-reports-third-105900193.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "56d240bf-5896-3ea2-b0ee-f07fab5797eb",
      "content": {
        "id": "56d240bf-5896-3ea2-b0ee-f07fab5797eb",
        "contentType": "STORY",
        "title": "Bristol Myers Squibb Reports Third Quarter Financial Results for 2025",
        "description": "",
        "summary": "PRINCETON, N.J., October 30, 2025--Bristol Myers Squibb Reports Third Quarter Financial Results for 2025",
        "pubDate": "2025-10-30T10:59:00Z",
        "displayTime": "2025-10-30T10:59:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/141a7ec95ffa7c8e9e23438ae818ddfc",
          "originalWidth": 1497,
          "originalHeight": 206,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/j9iBO7.NVCyQcDMlyTcqsg--~B/aD0yMDY7dz0xNDk3O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/141a7ec95ffa7c8e9e23438ae818ddfc.cf.webp",
              "width": 1497,
              "height": 206,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/HVxgWyaDVZ9UIM0FGNCRnA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/141a7ec95ffa7c8e9e23438ae818ddfc.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/bristol-myers-squibb-reports-third-105900193.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bristol-myers-squibb-reports-third-105900193.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BMY"
            },
            {
              "symbol": "CELG-RT"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-30T14:05:10+00:00",
    "headline": "Bristol Myers beats quarterly revenue estimates on strong Opdivo sales",
    "summary": "By Michael Erman and Puyaan Singh (Reuters) -Bristol Myers Squibb beat Wall Street estimates for third-quarter revenue on Thursday, as strong growth of its cancer immunotherapy and blood thinner",
    "url": "https://ca.finance.yahoo.com/news/bristol-myers-beats-quarterly-revenue-140510358.html",
    "source": "Reuters",
    "provider": "yfinance",
    "raw": {
      "id": "e332cf08-de8f-32f2-8c42-82ccc076f2ee",
      "content": {
        "id": "e332cf08-de8f-32f2-8c42-82ccc076f2ee",
        "contentType": "STORY",
        "title": "Bristol Myers beats quarterly revenue estimates on strong Opdivo sales",
        "description": "",
        "summary": "By Michael Erman and Puyaan Singh (Reuters) -Bristol Myers Squibb beat Wall Street estimates for third-quarter revenue on Thursday, as strong growth of its cancer immunotherapy and blood thinner",
        "pubDate": "2025-10-30T14:05:10Z",
        "displayTime": "2025-10-30T14:05:10Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/reuters.com/5732f88ea89fe8f631aaac48901687f2",
          "originalWidth": 800,
          "originalHeight": 516,
          "caption": "FILE PHOTO: Logo of global biopharmaceutical company Bristol-Myers Squibb is pictured at the headquarters in Le Passage, near Agen, France March 29, 2018. REUTERS/Regis Duvignau/File Photo",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/U9kITEzMqZBYR_MTJHEMZw--~B/aD01MTY7dz04MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/5732f88ea89fe8f631aaac48901687f2.cf.webp",
              "width": 800,
              "height": 516,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/lhFtH85KygZd7R0TIna1Vw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/5732f88ea89fe8f631aaac48901687f2.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Reuters",
          "url": "https://www.reuters.com/"
        },
        "canonicalUrl": {
          "url": "https://ca.finance.yahoo.com/news/bristol-myers-beats-quarterly-revenue-140510358.html",
          "site": "finance",
          "region": "CA",
          "lang": "en-CA"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bristol-myers-beats-quarterly-revenue-140510358.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BMY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]